Circulation. 1998;97:1223-1226
(Circulation. 1998;97:1223-1226.)
© 1998 American Heart Association, Inc.
Estrogens, Progestins, and Heart Disease
Can Endothelial Function Divine the Benefit?
Robert A. Vogel, MD;
; Mary C. Corretti, MD
From the Division of Cardiology, Department of Medicine, University of
Maryland School of Medicine, Baltimore, Md.
Correspondence to Robert A. Vogel, MD, University of Maryland Hospital, Room S3B06, 22 S Greene St, Baltimore, MD 21201. E-mail RVOGEL@heart.ab.umd.edu
Key Words: Editorials • endothelium • heart diseases • hormones
Coronary atherosclerosis
is a prevalent, preventable, but slow disease. Demonstrating the
clinical effect of an intervention requires at least 3 to 5 years, even
in high-risk populations. Despite considerable supportive observational
data, the value of hormone replacement therapy in the treatment of
coronary heart disease in postmenopausal women remains
uncertain.1 2 3 4 It is therefore very attractive to
look for intermediate biological outcomes that may more quickly predict
the results of event trials. One intermediate biological outcome, the
anatomic progression of coronary
atherosclerosis, has been shown to correlate with the
incidence of cardiovascular
events.5 Changes in angiographic disease
progression, however, even with clinically successful interventions
such as cholesterol lowering, do not occur in less than 1
to 2 years.6 The endothelium is
thought to play an important role in the genesis of
atherosclerosis, and changes in
endothelial function have been reported within an hour
of either estrogen administration or cholesterol
lowering.7 8 9 If changes in
endothelial function were found to predict the clinical
benefit of interventions, then drug and lifestyle changes could be
evaluated more rapidly. In this issue, Sorensen and
coworkers10 report that cyclical estradiol and
norethisterone hormone replacement therapy administered for 2.9±0.5
years did not improve endothelial function, measured as
brachial artery flow–mediated vasodilation. The authors conclude that
the addition of a progestin in a hormone replacement regimen may
counteract the beneficial effects of estrogen alone on
cardiovascular disease. If confirmed by other
investigations, this study suggests that clinical trials of combined
hormone replacement therapy will not find a beneficial effect . . . [Full Text of this Article]
This article has been cited by other articles:
|
|
|
|
 
P. D. Patel and R. R. Arora
Review: Endothelial dysfunction: A potential tool in gender related cardiovascular disease
Therapeutic Advances in Cardiovascular Disease,
April 1, 2008;
2(2):
89 - 100.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Saglam, U. Bozlar, F. Kantarci, H. Ay, B. Battal, and U. Coskun
Effect of Hyperbaric Oxygen on Flow-Mediated Vasodilation: An Ultrasound Study
J. Ultrasound Med.,
February 1, 2008;
27(2):
209 - 214.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Vogel
Eating, vascular biology, and atherosclerosis: a lot to chew on
Eur. Heart J.,
January 1, 2006;
27(1):
13 - 14.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. H. Slyper
What Vascular Ultrasound Testing Has Revealed about Pediatric Atherogenesis, and a Potential Clinical Role for Ultrasound in Pediatric Risk Assessment
J. Clin. Endocrinol. Metab.,
July 1, 2004;
89(7):
3089 - 3095.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. N. Thomas, P. Chook, M. Qiao, X. S. Huang, H. C. Leong, D. S. Celermajer, and K. S. Woo
Deleterious Impact of "High Normal" Glucose Levels and Other Metabolic Syndrome Components on Arterial Endothelial Function and Intima-Media Thickness in Apparently Healthy Chinese Subjects: The CATHAY Study
Arterioscler. Thromb. Vasc. Biol.,
April 1, 2004;
24(4):
739 - 743.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. K. Koh, J. Y. Ahn, D. K. Jin, B.-K. Yoon, H. S. Kim, D. S. Kim, W. C. Kang, S. H. Han, I. S. Choi, and E. K. Shin
Significant Differential Effects of Hormone Therapy or Tibolone on Markers of Cardiovascular Disease in Postmenopausal Women: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study
Arterioscler. Thromb. Vasc. Biol.,
October 1, 2003;
23(10):
1889 - 1894.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Gokce, J. F. Keaney Jr, L. M. Hunter, M. T. Watkins, Z. S. Nedeljkovic, J. O. Menzoian, and J. A. Vita
Predictive value of noninvasivelydetermined endothelial dysfunction for long-term cardiovascular events inpatients with peripheral vascular disease
J. Am. Coll. Cardiol.,
May 21, 2003;
41(10):
1769 - 1775.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Vogel
Vintners and vasodilators: are French red wines more cardioprotective?
J. Am. Coll. Cardiol.,
February 5, 2003;
41(3):
479 - 481.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. O. Bonetti, L. O. Lerman, and A. Lerman
Endothelial Dysfunction: A Marker of Atherosclerotic Risk
Arterioscler. Thromb. Vasc. Biol.,
February 1, 2003;
23(2):
168 - 175.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. C. Corretti, T. J. Anderson, E. J. Benjamin, D. Celermajer, F. Charbonneau, M. A. Creager, J. Deanfield, H. Drexler, M. Gerhard-Herman, D. Herrington, et al.
Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: A report of the International Brachial Artery Reactivity Task Force
J. Am. Coll. Cardiol.,
January 16, 2002;
39(2):
257 - 265.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Vita and J. F. Keaney Jr
Hormone Replacement Therapy and Endothelial Function: The Exception That Proves the Rule?
Arterioscler. Thromb. Vasc. Biol.,
December 1, 2001;
21(12):
1867 - 1869.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. C. Clarke, P. M. Schofield, A. A. Grace, J. C. Metcalfe, and H. L. Kirschenlohr
Tamoxifen Effects on Endothelial Function and Cardiovascular Risk Factors in Men With Advanced Atherosclerosis
Circulation,
March 20, 2001;
103(11):
1497 - 1502.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Vogel, M. C. Corretti, and G. D. Plotnick
The postprandial effect of components of the mediterranean diet on endothelial function
J. Am. Coll. Cardiol.,
November 1, 2000;
36(5):
1455 - 1460.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Schächinger, M. B. Britten, and A. M. Zeiher
Prognostic Impact of Coronary Vasodilator Dysfunction on Adverse Long-Term Outcome of Coronary Heart Disease
Circulation,
October 3, 2000;
(2000)
0.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
V. Schachinger, M. B. Britten, and A. M. Zeiher
Prognostic Impact of Coronary Vasodilator Dysfunction on Adverse Long-Term Outcome of Coronary Heart Disease
Circulation,
April 25, 2000;
101(16):
1899 - 1906.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Windecker, Y. Allemann, M. Billinger, T. Pohl, D. Hutter, T. Orsucci, L. Blaga, B. Meier, and C. Seiler
Effect of endurance training on coronary artery size and function in healthy men: an invasive followup study
Am J Physiol Heart Circ Physiol,
June 1, 2002;
282(6):
H2216 - H2223.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Gokce, J. F. Keaney Jr, L. M. Hunter, M. T. Watkins, J. O. Menzoian, and J. A. Vita
Risk Stratification for Postoperative Cardiovascular Events via Noninvasive Assessment of Endothelial Function: A Prospective Study
Circulation,
April 2, 2002;
105(13):
1567 - 1572.
[Abstract]
[Full Text]
[PDF]
|
|
|
